125 related articles for article (PubMed ID: 32001948)
1. Localization and Accumulation Studies of Dacomitinib in Rat Intestines and Skin by Immunohistochemistry.
Yamamoto Y; Saita T; Oka A; Kataoka H; Shin M
Acta Histochem Cytochem; 2019 Dec; 52(6):101-106. PubMed ID: 32001948
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical localization of afatinib in male rat intestines and skin after its oral administration.
Yamamoto Y; Saita T; Yamamoto Y; Sogawa R; Kimura S; Narisawa Y; Kimura S; Shin M
Acta Histochem; 2019 Nov; 121(8):151439. PubMed ID: 31500866
[TBL] [Abstract][Full Text] [Related]
3. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
Lavacchi D; Mazzoni F; Giaccone G
Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
[TBL] [Abstract][Full Text] [Related]
5. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Lau SCM; Batra U; Mok TSK; Loong HH
Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
[TBL] [Abstract][Full Text] [Related]
6. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats.
Van Sebille YZA; Gibson RJ; Wardill HR; Secombe KR; Ball IA; Keefe DMK; Finnie JW; Bowen JM
Int J Cancer; 2017 Jun; 140(12):2820-2829. PubMed ID: 28316082
[TBL] [Abstract][Full Text] [Related]
7. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Ramalingam SS; Jänne PA; Mok T; O'Byrne K; Boyer MJ; Von Pawel J; Pluzanski A; Shtivelband M; Docampo LI; Bennouna J; Zhang H; Liang JQ; Doherty JP; Taylor I; Mather CB; Goldberg Z; O'Connell J; Paz-Ares L
Lancet Oncol; 2014 Nov; 15(12):1369-78. PubMed ID: 25439691
[TBL] [Abstract][Full Text] [Related]
8. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
[TBL] [Abstract][Full Text] [Related]
9. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
Necchi A; Lo Vullo S; Perrone F; Raggi D; Giannatempo P; Calareso G; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Togliardi E; Colecchia M; Busico A; Gloghini A; Testi A; Mariani L; Salvioni R
BJU Int; 2018 Mar; 121(3):348-356. PubMed ID: 28921872
[TBL] [Abstract][Full Text] [Related]
10. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
11. Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer.
Mok T; Lee K; Tang M; Leung L
Future Oncol; 2014 Apr; 10(5):813-22. PubMed ID: 24799062
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
13. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Ellis PM; Shepherd FA; Millward M; Perrone F; Seymour L; Liu G; Sun S; Cho BC; Morabito A; Leighl NB; Stockler MR; Lee CW; Wierzbicki R; Cohen V; Blais N; Sangha RS; Favaretto AG; Kang JH; Tsao MS; Wilson CF; Goldberg Z; Ding K; Goss GD; Bradbury PA; ; ;
Lancet Oncol; 2014 Nov; 15(12):1379-88. PubMed ID: 25439692
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT).
Chiu JW; Chan K; Chen EX; Siu LL; Abdul Razak AR
Invest New Drugs; 2015 Aug; 33(4):895-900. PubMed ID: 25937431
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
[TBL] [Abstract][Full Text] [Related]
16. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.
Jänne PA; Ou SI; Kim DW; Oxnard GR; Martins R; Kris MG; Dunphy F; Nishio M; O'Connell J; Paweletz C; Taylor I; Zhang H; Goldberg Z; Mok T
Lancet Oncol; 2014 Dec; 15(13):1433-1441. PubMed ID: 25456362
[TBL] [Abstract][Full Text] [Related]
17. Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application.
Sun H; Wu YL
Future Oncol; 2019 Aug; 15(23):2769-2777. PubMed ID: 31401844
[TBL] [Abstract][Full Text] [Related]
18. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract][Full Text] [Related]
19. Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.
Santarpia M; Menis J; Chaib I; Gonzalez Cao M; Rosell R
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):831-840. PubMed ID: 31356117
[No Abstract] [Full Text] [Related]
20. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]